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KOBJECTIVE: The purpose of this study was to assess the effectiveness
of electronic fetal monitoring (EFM) alone and with additional ST analy-
sis (EFM ST) in laboring women with a singleton term pregnancy that
is in cephalic presentation in the prevention of metabolic acidosis by the
application of individual patient data metaanalysis.
STUDY DESIGN: We conducted an individual patient data metaanalysis
using data from 4 randomized trials, which enabled us to account for
missing data and investigate relevant subgroups. The primary outcome
was metabolic acidosis, which was defined as an umbilical cord-artery
pH7.05 and a base deficit that had been calculated in the extra cel-
lular fluid compartment 12 mmol/L. We performed 8 explanatory
subgroup analyses for 8 different endpoints.
RESULTS: We analyzed data from 12,987 women and their newborn
infants. Metabolic acidosis was present in 57 women (0.9%) in the e
at 36 weeks of gestation: an individual participant data metaanalysis. Am J Obste
See related editorial, page 163EFM ST group and 73women (1.1%) in the EFM alone group (relative
isk [RR], 0.76; 95% CI, 0.53–1.10). Compared with EFM alone, the
se of EFM ST resulted in a reduction in the frequency of instrumen-
al vaginal deliveries (RR, 0.90; 95% CI, 0.83–0.99) and fetal blood
amples (RR, 0.49; 95% CI, 0.44–0.55). Cesarean delivery rates were
omparable between both groups (RR, 0.99; 95%CI, 0.91–1.09). Sub-
roup analyses showed that EFM ST resulted in fewer admissions to
neonatal intensive care unit for womenwith a duration of pregnancy of
41 weeks (RR, 0.61; 95% CI, 0.39–0.95).
CONCLUSION: EFM ST does not reduce the risk of metabolic acido-
is, but it does reduce the need for instrumental vaginal deliveries and
etal blood sampling.
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MARCH 2013 AmericPerinatal asphyxia is associated withseveral short- and long-term com-
plications that vary from mild hypoxic
ischemic encephalopathy to cerebral
palsy and death.1-3 Fetal monitoring
uring delivery helps identify fetuses at
isk of asphyxia. A relatively newmethod
or continuous fetal monitoring is the
TAN method (Neoventa Medical,
othenburg, Sweden) in which the clas-
ification of the electronic fetal monitor
EFM) is combined with ST analysis of
he fetal electrocardiogram. Similar to
he postpartum electrocardiogram, in-
ormation can be evaluated about the
mplitude of the T-wave in relation to
he QRS-complex (T/QRS ratio) and the
onduction in the ST segment. Changes
n the fetal electrocardiogram in combi-
ation EFM abnormalities could be an
ndication of fetal hypoxia, as shown in
revious animal studies.4,5 Westgate etFrom the Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht
(Mr Schuit and Drs Groenwold and Moons), and the Department of Obstetrics and Gynecology,
University Medical Centre Utrecht (Drs Westerhuis, Visser, and Kwee), Utrecht, and the
Department of Obstetrics and Gynecology, Academic Medical Centre, Amsterdam (Dr Mol), The
Netherlands; the Department of Women and Child Health, Karolinska Institute, Stockholm (Dr
Amer-Wahlin), and the Department of Obstetrics and Gynecology, Clinical Sciences, Lund
University, Lund (Dr Marsˇál), Sweden; the Department of Obstetrics and Gynecology, Oulu
University Hospital, Oulu, Finland (Drs Ojala and Tekay); the Department of Obstetrics and
Gynecology, CHU Toulouse and Inserm UMR1027, University Toulouse III, Toulouse, France (Dr
Vayssière); and the Department of Obstetrics and Gynecology, University of Texas Medical
Branch, Galveston, TX (Dr Saade).
Received Sept. 4, 2012; revised Jan. 7, 2013; accepted Jan. 14, 2013.
K.G.M.M. received financial contribution for his research by the Netherlands Organization for
Scientific Research (project 9120.8004 and 918.10.615).
I.A-W. previously worked as a consultant for Neoventa Medical. All other authors report no conflict
of interest.
Presented as a poster at the 32th annual meeting of the Society for Maternal-Fetal Medicine,
Dallas, TX, Feb. 6-11, 2012.
Reprints: Ewoud Schuit, University Medical Centre Utrecht, Location Julius Centre for Health
Sciences and Primary Care, Department of Epidemiology, Stratenum 6.131, PO Box 85500, 3508
GA Utrecht, The Netherlands. E.Schuit@umcutrecht.nl.
0002-9378/$36.00 • © 2013 Mosby, Inc. All rights reserved. • http://dx.doi.org/10.1016/j.ajog.2013.01.028l6 were the first to conduct a random-





































Research Obstetrics www.AJOG.orgized controlled trial (RCT) on the effect
of intrapartum fetal electrocardiogram
monitoring. Four subsequent RCTs fo-
cused on automatically detected T/QRS
changes rather than absolute values of
T/QRS.7-10 All 5 RCTs were inconclu-
ive; 4 of the studies showed no statisti-
ally significant effect.6,8-10 In one study,
T analysis significantly reduced the in-
idence of metabolic acidosis. 7
To study the effect of ST analysis 
EFM compared with EFM alone, meta-
analyses were performed with the use of
aggregated data (ADMA).11-13 These
metaanalyses showed a nonsignificant
reduction ofmetabolic acidosis when in-
trapartum ST analysis was used. These
metaanalyses relied on published data.
Because not all RCTs reported all end-
points of interest, some endpoints were
excluded from the metaanalyses.11-13
Another limitationof thesemetaanalyses
was that they did not investigate sub-
groups.Obviously,more informationon
relevant endpoints and subgroups was
collected in the individual studies than
was reported. A metaanalysis that uses
individual participant data (IPDMA) al-
lows for a more thorough investigation
of endpoints and relevant subgroups by
taking all this information into account.
Furthermore, in IPDMA, it is possible to
account for missing data.
In view of the shortcomings of con-
ventional metaanalyses with the use of
ADMA, we performed an IPDMA using
data from RCTs to investigate the addi-
tional effect of ST analysis in EFM.
MATERIALS AND METHODS
This study was conducted based on a
previously written, but unpublished,
protocol. The reporting of the IPDMA
was carried out according to the pre-
ferred reporting items for systematic re-
views and metaanalyses (PRISMA)
guidelines.14
Objective
The main objective of this study was to
assess the effectiveness of the combina-
tion of ST analysis of the fetal electrocar-
diogram and EFM compared with EFM
alone in laboring women with a term
singleton pregnancy that was in cephalic
187.e2 American Journal of Obstetrics& Gynecolopresentation in the prevention of meta-
bolic acidosis by means of an IPDMA.
Search strategy and selection criteria
Trials were identified by a search the fol-
lowing electronic databases for phase III
trials of EFM  ST analysis compared
with EFMalone, in laboringwomenwith
a term singleton pregnancy in cephalic
presentation: Cochrane Central Regis-
ter of Controlled Trials, PubMed,
MEDLINE, Embase, ClinicalTrials.gov,
and controlled-trials.com, following the
search strategy of Becker et al.11 Two
review authors (E.S. and A.K.) inde-
pendently assessed inclusion criteria,
study quality, and risk of bias. Discre-
pancies were resolved by third author
(R.H.H.G.). The risk of bias was assessed
by 2 independent reviewers (E.S. and
A.K.) who used amodified version of the
risk of bias tool thatwas developedby the
Cochrane collaboration that contains
specific items that assess adequate se-
quence generation (ie, computer-gener-
ated random number, the use of a ran-
dom number table, or other truly
random process), allocation conceal-
ment (ie, web-based or telephone central
randomization), incomplete outcome
data, andother possible sources of bias.15
Selective outcome reporting was not
considered an issue because IPDMAs
rely on IPD rather than reported out-
comes. Studies were included if they had
a low risk of bias, were focused onT/QRS
changes of the fetal electrocardiogram,
were completed before Dec. 1, 2011, and
the principal investigators had provided
the IPD relating EFM  ST analysis vs
FM alone. The relevant baseline char-
cteristics and outcomes of interest,
hich are described later, were extracted
y one of the authors (E.S.). Data quality
eg, discrepancies between published
nd shared data) was assessed indepen-
ently by 2 review authors (E.S. and




dosisBDecf, defined as an umbilical cord-
artery pH below 7.05 and a base deficit
calculated in the extra cellular fluid com-
partment (BDecf) above 12 mmol/L, cal-
gy MARCH 2013culated with the Sigaard-Andersen algo-
rithm.16 Secondary outcomes included
etabolic acidosisBDblood that is defined
as an umbilical cord-artery pH 7.05
and a base deficit calculated in blood
(BDblood) 12 mmol/L. Additional sec-
ndary outcomes were cord-artery pH
7.15, cord-artery pH 7.05, cord-ar-
ery pH 7.00, BDecf 12 mmol/L,
BDblood 12 mmol/L, 5-minute Apgar
core7, admission to a neonatal inten-
ive care unit (NICU), hypoxic-ischemic
ncephalopathy, intubation, seizures,
erinatal death, frequency of fetal blood
amples, cesarean delivery, vaginal in-
trumental delivery, and the total fre-
uency of operative deliveries. To in-
rease comparability with a currently
ngoing RCT that is being conducted by
he National Institute of Child Health
evelopment (NICHD) in the United
tates, we also used their primary out-
ome as one of our secondary outcomes.
his outcome is a composite of intrapar-
um fetal death, neonatal death, Apgar
core of3 at 5minutes, seizure(s), cord
rtery pH7.05 andBDecf12mmol/L,
ntubation for ventilation at delivery, or
resence of neonatal encephalopathy.17
Subgroups
Secondary objectives were to assess the
additional effect of ST analysis in differ-
ent subgroups differentiated by the fol-
lowing: (1) gestational age defined as
37weeks, 37-40weeks, 40-41weeks, or
41weeks; (2) parity defined as nulli- or
multiparous; (3) previous cesarean de-
livery (yes/no); (4) maternal diabetes
mellitus (yes/no); (5) induced onset of
labor (yes/no); (6) meconium-stained
amniotic fluid (yes/no); (7) epidural an-
esthesia (yes/no); and (8) birthweight
below the tenth percentile (yes/no). The
subgroup effects were investigated for
the primary outcome, metabolic acido-
sisBDecf, and the following secondary
outcomes: composite neonatal outcome,
cesarean delivery, need for intubation,
NICU admission, hypoxic-ischemic en-
cephalopathy, instrumental vaginal de-
livery, and fetal blood sampling.
Analysis
All analyses were performed on all ran-
































www.AJOG.org Obstetrics Researchterm singleton in cephalic presentation
with an indication for internal EFM.
The analyses were conducted on an in-
tention-to-treat basis (ie, according to
the treatment assigned by randomiza-
tion, regardless of treatment actually
received).
Descriptive comparisons between studies
were conducted to assess between-study
differences. Treatment effects on the pri-
mary and secondary outcomes were esti-
mated by means of a random effects log-
binomial model. The measure of
association was the risk ratio (RR), with
an RR 1 indicating treatment benefit.
oth heterogeneity across studies and
ependency between data that origi-
ated from the same study were taken
nto account by fitting a random inter-
ept for each original study bymeans of a
andom effects model. The presence of
eterogeneity in outcomes across trials
as assessed using the I2 measure, and
he values were interpreted as follows:
% indicates no observed heterogeneity;
5%, 50%, and 75% indicate low, mod-
TABLE 1














Exclusion criteria None mentioned in
article
...................................................................................................................





Allocation concealment Yes; adequate
...................................................................................................................
Sequence generation Yes; adequate
...................................................................................................................




Blinding of outcome assessors Yes; adequate
...................................................................................................................
Participant with incomplete
primary outcome data, n (%)
731 (14.5)
...................................................................................................................
STAN S21 and STAN S31; Neoventa Medical, Gothenburg, Sw
EFM, electronic fetal monitoring.
a STAN S21 fetal heart monitor that provides EFM automatic
ST analysis of the fetal electrocardiogram.
Schuit. Individual participant data metaanalysis of fetal Srate, and high heterogeneity, respec- gively.18 If necessary, analyses were ad-
justed for variables that were used in
stratified randomization (eg, center
and/or parity) by including them as
covariates in the regression model. Ad-
ditionally, we calculated the number
needed to test (NNT) with 95%CI when
an association was found to be statisti-
cally significant. TheNNT is comparable
with the numbers needed to treat but re-
fers to the number of tests (in this case
the number of laboring women who
need to be monitored with EFM  ST
analysis) to prevent 1 case of metabolic
acidosisBDecf.
To investigate subgroup effects, the
treatment effects were investigated with
an interaction term between the alloca-
tion and the subgroup in the regression
model defined earlier. When a signifi-
cant interaction was present, the treat-
ment effect was then estimated within
strata based on that subgrouping vari-
able. For the primary outcome, meta-
bolic acidosisBDecf, which is a stratified
nalysis across the predefined sub-
lled studies on ST analysis  EFM co





Laboring women at 36 weeks



















Yes; adequate Yes; adequat
.........................................................................................................................
Yes; adequate Yes; adequat
.........................................................................................................................
No; not possible No; not poss
.........................................................................................................................
Yes; adequate Yes; adequat
.........................................................................................................................
36 (2.4) 34 (4.3)
.........................................................................................................................
n.
nalysis of the fetal electrocardiogram; b STAN S31 fetal heart mon
alysis. Am J Obstet Gynecol 2013.roups, was performed despite the pres- w
MARCH 2013 Americnce of a significant interaction in the
egression model to investigate the di-
ection of the additional effect of
T analysis in different strata of the
ubgroups.
The 4 RCTs had different proportions
f missing values for the primary out-
ome that ranged from 2.4–14.5% (Ta-
le 1). Because these missing values are
ften selectively missing, which was also
he case in these RCTs (Appendix; Sup-
lementary Tables 1-3; and Appendix 3
f Westerhuis et al10), a complete case
nalysis is likely to yield biased results.19
To avoid this bias, we used observed pa-
tient characteristics to impute missing
data by means of multiple imputations.
Missing data were imputed (10 times)
with the use of a logistic regression
model that included the following vari-
ables: center, allocation, parity, neonatal
sex, Apgar score at 1 and 5 minutes, ar-
terial pH, arterial BDblood, arterial BDecf,
rterial pCO2, venous pH, venous
CO2, birthweight, and indication for
he intervention. The primary outcome













Laboring women at 36 weeks of
gestation; singleton fetus; cephalic
position; age 18 years;




None mentioned in article
..................................................................................................................











































ST a itor (as included in the imputationmodel to





























Research Obstetrics www.AJOG.orgimprove imputations for missing data
on other variables of interest. Missing
data were imputed within each individ-
ual study before pooling the studies.20
Analyses were performed individually
on each of the 10 imputed data sets and
results were pooled using standard
methods (Rubin’s rule).21
Statistical analyses andmultiple impu-
tations were performed with the use of R
software (version 2.15.0; The R Founda-
tion for Statistical Computing, 2012).
RESULTS
Included studies
Six studies on ST analysis in laboring
women with a term singleton pregnancy
that was in cephalic presentation were
FIGURE
Flow diagram of study selection





































The figure shows the process from the identificati
data metaanalysis.
T/QRS, T-wave in relation to the QRS-complex.
Schuit. Individual participant data metaanalysis of fetal ST aidentified, of which 4 womenmet the in-
187.e4 American Journal of Obstetrics& Gynecoloclusion criteria (Figure; Table 1).7-10 The
tudyof Strachan et al22was excludedbe-
ause it studied the PR waveform of the
etal electrocardiogram rather than the
T segment. Even though the study of
estgate et al6 focused on T/QRS
changes, the study was excluded because
the ST-analysis method that was used
was different than the methods used in
more recent studies. In the study by
Westgate et al, the STAN 8801 recorder
(Neoventa Medical) was used; the other
studies used the STAN S21 and/or S31.
Although investigating T/QRS changes,
the threshold for performance of an in-
tervention was based on the absolute
T/QRS ratio and not a change in T/QRS
ratio. Furthermore, biphasic ST changes


















o the inclusion of studies in this individual patient
sis. Am J Obstet Gynecol 2013.were not incorporated in the guideline. t
gy MARCH 2013Another important difference was that
ST changes were identified by visual
analysis. The STAN S21 and S31 moni-
tors provide an automatic assessment of
the ST changes and give an automatic
warning in case of significant changes.
Datasets that contained IPD were ob-
tained for 4 RCTs: Amer-Wahlin et al7,
Ojala et al8, Vayssière et al,9 andWester-
uis et al.10
The characteristics of the included
studies are shown in Table 1. In general,
all studies had similar inclusion and ex-
clusion criteria. The only exception was
the study of Vayssière et al, which in-
cluded only women who had an abnor-
mal EFM or thick meconium-stained
amniotic fluid during labor. Because all
studies also used similar interventions
and controls, these studies can be con-
sidered to have a high degree of homo-
geneity. The study of Westerhuis et al10
stratified the randomization of partici-
pants to EFM  ST analysis or EFM
lone by center and parity (nulli- vs
ultiparous).
All trials used adequate methods to
enerate allocation sequences and ade-
uate methods for allocation conceal-
ent (Table 1). Because of the nature of
he intervention, the blinding of partici-
ants and medical professionals was not
ossible. Blinding the assessors to the
utcome was adequate in all trials. The
umber of women with incomplete pri-
ary outcome data differed per study
ut could be accounted forwithmultiple
mputations. No other problems were
ound that could lead to bias.
Individual data from 6524 partici-
ants who were allocated to EFM  ST
nalysis of the fetal electrocardiogram
nd 6463 participants who were allo-
ated to EFM alone were included in this
PDMA. The baseline characteristics of
ombined participants by treatment
roups were similar (Table 2).
Overall effects of ST analysis of the
fetal electrocardiogram
Table 3 shows the effect of ST analysis
EFM compared with EFM alone for the
primary and secondary outcomes. The
primary outcome, metabolic acidosisBDecf,

































www.AJOG.org Obstetrics Researchgroup and 73 women (1.1%) in the EFM
alone group (RR, 0.76; 95% confidence
interval [CI], 0.53–1.10). Using a 2-step
approach (ie, analysis like an ADMA),
we found a moderate amount of hetero-
geneity for the primary outcome be-
tween the studies (I2  42%; 95% CI,
–81%; Tau2 0.09).
The frequency of fetal blood sam-
plings (RR, 0.49; 95% CI, 0.44–0.55;
NNT, 13; 95% CI, 12–16) and of ins-
trumental vaginal deliveries (RR, 0.90;
95% CI, 0.83–0.99; NNT, 69; 95% CI,
38–357) were reduced significantly by
EFM  ST analysis. ST analysis  EFM
did not reduce the incidence of any other
secondary outcome. The results were
similar even after correction for strati-
fied randomization.
Subgroup analyses
EFM  ST analysis did not show a sig-
nificant effect formetabolic acidosisBDecf
(Table 4), composite neonatal outcome,
instrumental vaginal delivery, cesarean
delivery, need for intubation, and hy-
TABLE 2








Mean maternal age, ya NA
...................................................................................................................






Diabetes mellitus, n (%) 104 (2)
...................................................................................................................




Gestational age, wka 39.6  1.6
...................................................................................................................






Epidural anesthesia, n (%) 1957 (39)
...................................................................................................................
Birthweight (g)a 3567  531
...................................................................................................................
All numbers are based on the data as shared by the individua
EFM, electronic fetal monitoring; NA, not available.
a Data are presented as mean SD; b Percentage based on stu
Schuit. Individual participant data metaanalysis of fetal Spoxic-ischemic encephalopathy accord- 0ing to gestational age, parity, previous
cesarean delivery, maternal diabetes
mellitus, induced onset of labor, meco-
nium-stained amniotic fluid, epidural
anesthesia, or birthweight below the
tenth percentile. It must be noted that
information regarding previous cesar-
ean delivery was not available from
Amer-Wahlin et al7 and Ojala et al.8
Significant subgroup effects were
found for 2 secondary outcomes: fetal
blood sampling andNICUadmission ac-
cording to gestational age at delivery and
epidural anesthesia (Table 5). EFM ST
nalysis reduced the fetal blood sampling
ore in womenwith epidural anesthesia
han in women without anesthesia (RR,
.46; 95% CI, 0.40–0.52 vs RR, 0.61;
5% CI, 0.49–0.75; probability value of
nteraction, .03). This is rather uninfor-
ative, however, because both benefit
rom additional ST analysis. Further-
ore, EFM  ST analysis reduced the
requency of NICU admissions in
omen with a gestational age at delivery
f 41 weeks (RR, 0.61; 95% CI,












28.0  5.5 30.0  5.7 32.0
.........................................................................................................................
757 (51) 575 (72) 3236 (5
.........................................................................................................................
NA 49 (6) 716 (1
.........................................................................................................................
115 (8) 41 (5) 169 (3
.........................................................................................................................
733 (50) NA 2668 (4
.........................................................................................................................
40.1 1.3 40.0  1.9 40.2
.........................................................................................................................
277 (19) 257 (36) 2341 (4
.........................................................................................................................
260 (18) 121 (15) 1471 (2
.........................................................................................................................
793 (54) 725 (91) 2389 (4
.........................................................................................................................
3605 503 3243  500 3544
.........................................................................................................................
arch groups.
of Vayssiere et al9 and Westerhuis et al10; c Percentage is based on
alysis. Am J Obstet Gynecol 2013..39–0.95).
MARCH 2013 AmericCOMMENT
Principal findings of the study
This metaanalysis that is based on
IPDMA from 4 randomized clinical trials
of ST analysis showed that EFM  ST
analysis of the fetal electrocardiogram
does not reduce metabolic acidosisBDecf
and cesarean delivery rates but reduces
the frequency of fetal blood sampling
and instrumental vaginal deliveries com-
pared with EFM alone. Subgroup analy-
ses showed an additional advantage of
ST analysis for women with a gestational
age of 41 weeks in the reduced fre-
quency of NICU admissions.
Comparison of the findings
with previous studies
The results of this study are in line
with the 3 previously published AD-
MAs.11-13 The slight differences in the
oint estimates for the primary outcome
etween the metaanalyses and this IP-
MA are explained by the inclusion of
he trial ofWestgate et al6 in theADMAs.








.8 31.0  5.3 31.0  5.3
..................................................................................................................
3851 (59) 3823 (59)
..................................................................................................................
370 (11)b 395 (12)b
..................................................................................................................
261 (4) 168 (3)
..................................................................................................................
2860 (47)c 2929 (48)c
..................................................................................................................
.4 39.9  1.5 40.0  1.6
..................................................................................................................
1879 (29) 1862 (29)
..................................................................................................................
1476 (23) 1519 (24)
..................................................................................................................
2898 (44) 2966 (46)
..................................................................................................................
8 3546  527 3536  525
..................................................................................................................


























dies studietional ST analysis significantly decreases








Research Obstetrics www.AJOG.orgthe incidence of metabolic acidosisBDecf.
herefore, exclusion of this study from
TABLE 3
Primary and secondary outcomes p
effect of ST analysis  EFM compa
Outcome





















Arterial pH 7.15 997 (20) 218 (15)
..........................................................................................................
Arterial pH 7.05 178 (4) 28 (2)
..........................................................................................................
Arterial pH 7.00 67 (1) 7 (0)
..........................................................................................................
BDecf 12 mmol/L 150 (3) 34 (2)
..........................................................................................................
BDblood 12 mmol/L NA 83 (6)
..........................................................................................................
Apgar at 5 minutes 7 61 (1) 17 (1)
..........................................................................................................
Admitted to a neonatal
intensive care unit




7 (0) 1 (0)
..........................................................................................................
Need for intubation NA 12 (1)
..........................................................................................................
Seizures NA 2 (0)
..........................................................................................................




75 (1) 28 (2)
..........................................................................................................
Fetal blood sampling NA 166 (11)
..........................................................................................................
Cesarean delivery 447 (9) 82 (6)
..........................................................................................................
Fetal distress 194 (4) 30 (2)
..........................................................................................................




542 (11) 149 (10)
..........................................................................................................
Fetal distress 239 (5) 84 (6)
..........................................................................................................
Failure to progress 261 (5) 30 (2)
..........................................................................................................




433 (9) 114 (8)
..........................................................................................................
Because of failure to
progress
478 (9) 67 (5)
...................................................................................................................
All numbers are based on the data as shared by the individua
BDblood, base deficit calculated in blood; BDecf, base deficit c
calculated.
a Estimated with the use of a random effects model in which a
of intrapartum fetal death, neonatal death, Apgar score of3
encephalopathy.
Schuit. Individual participant data metaanalysis of fetal She IPDMAgives a conservative result on I
187.e6 American Journal of Obstetrics& Gynecolohe added value of ST analysis. Second,
he IPDMA accounted for missing data.
study and the overall











9 5667 6524 6463 —
.........................................................................................................................
.........................................................................................................................
9 (2) 46 (1) 57 (0.9) 73 (1.1) 0
.........................................................................................................................
.........................................................................................................................
107 (2) 58 (1.6)a 72 (2.0)a 0
.........................................................................................................................
9 (20) 861 (15) 1118 (17) 1117 (17) 0
.........................................................................................................................
9 (2) 117 (2) 165 (2.5) 187 (2.9) 0
.........................................................................................................................
4 (2) 50 (1) 65 (1.0) 72 (1.1) 0
.........................................................................................................................
3 (15) 204 (4) 266 (4) 246 (4) 1
.........................................................................................................................
413 (7) 244 (7)a 251 (7)a 0
.........................................................................................................................
3 (2) 76 (1) 89 (1.4) 78 (1.2) 1
.........................................................................................................................
0 (1) 86 (2) 258 (4) 274 (4) 0
.........................................................................................................................
2 (0) 3 (0.1) 7 (0.2) 0
.........................................................................................................................
8 (1) 22 (3) 16 (1.1) 26 (1.7) 0
.........................................................................................................................
2 (0) 9 (1) 4 (0.3) 9 (0.6) 0
.........................................................................................................................
1 (0) 5 (0.1) 5 (0.1) 4 (0.1) 1
.........................................................................................................................
3 (4) 91 (2) 101 (1.6) 125 (1.9) 0
.........................................................................................................................
6 (45) 879 (16) 460 (12) 941 (24) 0
.........................................................................................................................
9 (26) 796 (14) 768 (12) 766 (12) 0
.........................................................................................................................
9 (15) 164 (3) 253 (4) 254 (4) 0
.........................................................................................................................
509 (9) 388 (6) 375 (6) 1
.........................................................................................................................
6 (28) 815 (14) 823 (13) 909 (14) 0
.........................................................................................................................
1 (20) 337 (6) 393 (6) 428 (7) 0
.........................................................................................................................
361 (6) 305 (5) 347 (6) 0
.........................................................................................................................
5 (55) 1611 (28) 1591 (24) 1675 (26) 0
.........................................................................................................................
0 (35) 501 (9) 646 (10) 682 (11) 0
.........................................................................................................................
870 (15) 694 (11) 722 (12) 0
.........................................................................................................................
arch groups.
ted in the extra cellular fluid compartment; CI, confidence interv
m intercept was fitted for each individual study; b Percentage is b
minutes, seizure(s), cord artery pH of7.05 and BDecf of12 m
alysis. Am J Obstet Gynecol 2013.mputation of missing values resulted in
gy MARCH 2013additional cases (15%) of metabolic











0.53–1.10) .13 NC 42 (0–81)
..................................................................................................................
..................................................................................................................
0.58–1.16) .25 NC 83 (56–93)
..................................................................................................................
0.91–1.08) .79 NC 0 (0–84)
..................................................................................................................
0.70–1.09) .20 NC 68 (6–89)
..................................................................................................................
0.62–1.26) .48 NC 57 (0–86)
..................................................................................................................
0.90–1.29) .42 NC 0 (0–27)
..................................................................................................................
0.82–1.16) .80 NC 0 (0–44)
..................................................................................................................
0.84–1.54) .41 NC 0 (0–0)
..................................................................................................................
0.78–1.09) .32 NC 0 (0–0)
..................................................................................................................
0.11–1.64) .21 NC 0 (0–68)
..................................................................................................................
0.35–1.20) .16 NC 18 (0–92)
..................................................................................................................
0.14–1.51) .20 NC 0 (0–65)
..................................................................................................................
0.33–4.61) .75 NC 0 (0–75)
..................................................................................................................
0.62–1.05) .10 NC 0 (0–82)
..................................................................................................................
0.44–0.55)  .0001 13 (12–16) 9 (0–91)
..................................................................................................................
0.91–1.09) .91 NC 18 (0–87)
..................................................................................................................
0.83–1.17) .87 NC 42 (0–81)
..................................................................................................................
0.90–1.18) .70 NC 55 (0–87)
..................................................................................................................
0.83–0.99) .02 69 (38–357) 0 (0–77)
..................................................................................................................
0.80–1.05) .19 NC 1 (0–85)
..................................................................................................................
0.75–1.01) .07 NC 0 (0–87)
..................................................................................................................
0.88–1.01) .10 NC 0 (0–79)
..................................................................................................................
0.84–1.05) .26 NC 50 (0–84)
..................................................................................................................
0.86–1.05) .31 NC 65 (0–90)
..................................................................................................................
M, electronic fetal monitoring; NA, not available, NC, not
on studies of Ojala et al8 and Westerhuis et al10; c Composite








































































www.AJOG.org Obstetrics ResearchEFM-only group. Because of the increase
in numerator (more cases of metabolic
acidosisBDecf) and the denominator (no
participants with missing outcome val-
ues, so all participants were included in
the analyses), the estimated effect of ST
analysis was expected to be different
from the ADMAs.
Thepoint estimate ofmetabolic acido-
TABLE 4





















































10th percentile 4/667 (0.6%)
..........................................................................................................




CI, confidence interval; EFM, electronic fetal monitoring.
a n 6524; b n 6463; c Estimated with the use of a rando
Westerhuis et al.10
Schuit. Individual participant data metaanalysis of fetal SsisBDecf in this study is consistent with oonly 2 of the 4 included studies and was
opposite to the effects found by Ojala et
al8 and Vayssiere et al.9 It is unclear what
ight have caused this difference. Vays-
ière et al used slightly different inclusion
riteria (Table 1), which may have led to
he inclusion of women who were at
igher risk (Table 2) and potentiallymay
ave influenced the effect of ST analysis
ecf in relevant subgroups
FM alone














































EFM  ST better EF
.........................................................................................................................
fects model in which a random intercept was fitted for each indiv
alysis. Am J Obstet Gynecol 2013.nmetabolic acidosisBDecf. However, the e
MARCH 2013 Americinclusion criteria of Ojala et al were very
similar to the studies of Amer-Wahlin
et al7 and Westerhuis et al.10 It must be
noted that the studies by Ojala et al and
Vayssière et al were not powered to find a
difference in metabolic acidosisBDecf.
espite these differences, the baseline
haracteristics were comparable. How-
ver, there was amoderate degree of het-
Relative risk






































































































m ef idualrogeneity among the primary outcomes




































































Research Obstetrics www.AJOG.orgin the 4 studies. This heterogeneity is
likely a result of different directions of
the effect of ST analysis in the individual
studies, with the studies of Ojala et al8
and Vayssière et al9 that showed RRs1
harmful) and those of Amer-Wahlin et
l7 andWesterhuis et al10 that foundRRs
1 (beneficial). Given the amount of
eterogeneity, a fixed effect assumption
as considered unrealistic for the out-
omes; we therefore used random effects
odels that were similar to the ADMAs
o account for this heterogeneity.
Strengths and limitations
A potential problem in ADMA is that
primary outcomes of clinical trials and
subgroup definitions can differ between
trials, whichmakes it difficult to pool the
results of different studies. An IPDMA
overcomes this problem because it in-
volves synthesis of individual level data
from clinical trials, which allows for
more flexibility in the choice of end-
points, subgroups, potential harms, data
analysis, and handling of missing data.
Furthermore, IPDMA allows standard-
ization of inclusion and exclusion crite-
ria across studies, which is independent
of bias that may arise through selective
reporting.23 Therefore, an IPDMAoffers
more reliable conclusion on the effec-
TABLE 5



























CI, confidence interval; EFM, electronic fetal monitoring; NC, n
a n 6524; b n 6463; c Estimated with the use of a rando
Schuit. Individual participant data metaanalysis of fetal Siveness of ST analysis. m
187.e8 American Journal of Obstetrics& GynecoloTo put our results into context, a few
imitations must be addressed. All stud-
es that were included in the IPDMA that
egistered information on fetal blood
ampling showed a clear effect of ST
nalysis on the use of fetal blood sam-
ling.8-10 Fetal blood sampling is a rela-
ively invasive procedure and is used as
n adjunct test whenever the fetal heart
ate monitoring is indeterminate. The
esults of the studies and our IPDMA in-
icate that ST analysis replaced fetal
lood sampling as the adjunct test. Be-
ause fetal blood sampling was available
n the countries that were included in the
tudy, it might be difficult to generalize
hese results to countries where fetal
lood sampling is not used. Comparison
ith the results of the ongoing NICHD
rial in the United States will be particu-
arly interesting.
To investigate the effect of the algo-
ithm that was used to calculate the
Dblood and to be able to use umbilical
ord gas acid-base data from the studies
f Amer-Wahlin et al7 and Vayssiere et
l,9 which did not record BDblood, a sen-
itivity analysis was performed. In this
ensitivity analysis, the BDblood was cal-
ulated by the Corning and the Roche
lgorithms, which use a fixed value for
he hemoglobin concentration (9.3
ry in relevant subgroups
EFM alone















EFM  ST better EFM alone b
.........................................................................................................................
alculated.
fects model in which a random intercept was fitted for each indiv
alysis. Am J Obstet Gynecol 2013.mol/L).24 Including metabolic acido-
gy MARCH 2013sisBDblood calculated with these algo-
ithms in the sensitivity analysis, the ef-
ect of additional ST analysis was found
o be similar to the results in Table 3
data not shown).
Ojala et al8 excluded 11 women and
esterhuis et al10 excluded14women af-
er randomization because it was discov-
red later that they did not fulfill the in-
lusion criteria. Technically, this means
hat analyses in the studies, and therefore
lso in this IPDMA, were not performed
ccording to the intent-to-treat princi-
le. However, because the excluded
omen did not fulfill the inclusion crite-
ia, it was justified to leave them out of
he analyses.
Clinical implications
EFM  ST analysis leads to a reduction
n the frequency of operative vaginal
eliveries and fetal blood samples.
lthough the incidence of metabolic
cidosisBDecf was reduced by 25%, this
eduction was not statistically signifi-
ant, which might be due to its low inci-
ence of 1.0%.This incidence in the con-
rol group was much lower than
nticipated by the sample size calcula-
ions that were used by Amer-Wahlin et
l7 (1.3%) and Westerhuis et al10





(95% CI) P value
.03
..................................................................................................................
0.46 (0.40–0.52) 8 (7–9)
..................................................................................................................
0.61 (0.49–0.75) 37 (27–60)
..................................................................................................................
..................................................................................................................
1.12 (0.75–1.66) NC Reference
..................................................................................................................
1.00 (0.78–1.27) NC .62
..................................................................................................................
0.88 (0.59–1.30) NC .36
..................................................................................................................





















































































www.AJOG.org Obstetrics ResearchEFM-alone group because of the specific
STAN clinical guidelines training (Haw-
thorne effect). It is important to note
that, although adverse neonatal outcome
might be a more clinically relevant out-
come, additional ST analysis did not lead
to a significant reduction. Therefore, re-
sults of the ongoing RCT that is being
carried out by the NICHD in the United
States in which the primary outcome
is adverse neonatal outcome will be of
crucial importance in guiding future
management.17
Given the results of our IPDMA, we
believe that ST analysis has added value
in EFM, especially in hospitals where fe-
tal blood samples are performed. STAN
should be introduced into practice care-
fully, taking into account the learning
curve. The favorable effect of ST analysis
in the study by Amer-Wahlin et al7 was
observedmainly in the secondpart of the
trial. The interimanalysis showed several
avoidable protocol violations in partici-
pants who gave birth to babies withmet-
abolic acidosisBDecf. These cases resulted
in structured feedback and renewed
training.25 Recent observational studies
that have investigated the effects of long-
term use of ST analysis have shown a de-
crease in the incidence of metabolic aci-
dosisBDecf over time.
25-27 Furthermore,
he cases of adverse neonatal outcome
hat are described in the literature
ainly are due to problems with the in-
erpretation of the EFM or violation of
uidelines,28,29 which further supports
the hypothesis that the real impact of ST
analysis is still unknown.
Implications for research
As mentioned by Neilson,30 little infor-
mation about the long-term develop-
ment of the infants who participated in
the studies exists. A short follow-up in
the Swedish RCT showed a decreased
number of neonates with moderate or
severe neonatal encephalopathy in the
ST analysis arm.31 A long-term fol-
ow-up study of the Dutch RCT is cur-
ently ongoing. Follow-up studies
hould provide more insight into long-
erm behavioral and neurologic out-
omes, which in turn will allow for the
nvestigation of long-term cost-effec-
iveness. However, because there alreadyeems to be a clear association between
eonatal acidosis and long-term poor
eurologic outcome,2 we believe that
eonatal asphyxia, which is defined as
etabolic acidosis in the umbilical ar-
ery, is the best available surrogate
arker.
Metabolic acidosis, which is related to
erinatal and long-term outcomes such
s neonatal mortality, hypoxic ischemic
ncephalopathy, intraventricular hem-
rrhage or periventricular leukomalacia,
nd cerebral palsy,2 is considered to be
an intermediate outcome (ie, a proxy for
other outcomes). The incidence of met-
abolic acidosis hardly tops 1%, which
means that trials will need substantial
sample sizes to prove a statistically signif-
icant treatment effect. It is therefore de-
batable whether future studies should use
this outcome. Instead, we would like to
suggest the use of a neonatal outcome that
is composed of clinical outcomes that in-
clude moderate and severe perinatal as-
phyxia as defined by theAmericanCollege
of Obstetricians and Gynecologists32 and
erinatal death.Moreover, long-termout-
omes (eg, neurodevelopmental delay)
hould be of interest in future studies, es-
ecially because the long-term effects of
FMaloneandEFMSTanalysis arecur-
ently unknown. Furthermore, maternal
utcomes are clinically important as well,
speciallyacesareandelivery thatmayhave
oth short- and long-term consequences.
This IPDMAdid not show a reduction
f metabolic acidosis for those pregnan-
ies that were monitored with ST analy-
is compared with EFM alone but did
how a reduced frequency of operative
eliveries and fetal blood sampling.
onsequently, such discrepancies call
or formal cost-effectiveness assessment
f ST analysis compared with EFM
lone. Two up-to-date formal cost-effec-
iveness studies have been performed.33,34
One study, a long-term cost-effective-
ness study based on a probabilistic deci-
sion model with the use of Swedish ma-
ternity ward data, showed that ST
analysis is cost-effective in comparison
with EFM alone.33 The other study, a
ost-effectiveness study based on the
tudy of Westerhuis et al,10 concluded
that the additional costs of monitoring
by ST analysis are very limited when
MARCH 2013 Americcompared with monitoring with EFM
only and very low compared with the to-
tal costs of delivery.34 Because the results
n this IPDMA are comparable with the
esults of the study on which the latter
ost-effectiveness analysis was based, we
elieve that the results of this cost-effec-
iveness analysis can be translated to this
PDMA. To reach a final conclusion on
he cost-effectiveness of ST analysis, it
ay be necessary to perform a formal
nd extensive cost-effectiveness study
ith the use of all the available IPDMA
hat were collected in this metaanalysis.
owever, this fell outside the scope of
he current IPDMA study.
In conclusion, this large IPDMA adds
o the literature that the addition of ST
nalysis to cardiotocography in fetal
onitoring does not reduce the inci-
ence of metabolic acidosisBDecf, but
does reduce the frequency of instrumen-
tal vaginal deliveries and the need for fe-
tal blood sampling. f
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observed (n  1308)
Patients with at
least 1 missing value
(n  164) P valuea
Patient age at delivery, yb 27.8  5.5 27.8  5.2 .97
................................................................................................................................................................................................................................................................................................................................................................................
Gestational age at delivery, wkb 40.1  1.3 40.1  1.1 .76
................................................................................................................................................................................................................................................................................................................................................................................
Nulliparous, n (%) 628 (48) 86 (53) .29
................................................................................................................................................................................................................................................................................................................................................................................
Previous cesarean delivery, n (%) NA NA NA
................................................................................................................................................................................................................................................................................................................................................................................
Prolonged pregnancy: at least 42 wk, n (%) 56 (4) 4 (3) .40
................................................................................................................................................................................................................................................................................................................................................................................
Maternal diabetes mellitus, n (%) 99 (8) 16 (10) .32
................................................................................................................................................................................................................................................................................................................................................................................
Meconium-stained amniotic fluid, n (%) 233 (18) 27 (19) .90
................................................................................................................................................................................................................................................................................................................................................................................
Epidural anesthesia, n (%) 718 (55) 75 (46) .03
................................................................................................................................................................................................................................................................................................................................................................................
Induction of labor, n (%) 245 (19) 32 (22) .46
................................................................................................................................................................................................................................................................................................................................................................................
Birthweight, gb 3611  502c 3561  513c .24c
................................................................................................................................................................................................................................................................................................................................................................................
Birthweight 2500 g, n (%) 22 (2) 5 (3) .31
................................................................................................................................................................................................................................................................................................................................................................................
Neonatal female sex, n (%) 654 (50) 69 (48) .76
................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery pH 7.05; BDecf 12 mmol/L, n (%) 14 (1) 2 (2) .95................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery pH 7.05; BDblood 12 mmol/L, n (%) 21 (2) 2 (2) .74................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery pH 7.15, n (%) 192 (15) 23 (18) .39
................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery pH 7.05, n (%) 25 (2) 3 (2) 1.00
................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery pH 7.00, n (%) 6 (0.5) 1 (1) .87
................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery BDecf 12, n (%) 68 (5) 9 (8) .38................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery BDblood 12, n (%) 73 (6) 8 (7) .72................................................................................................................................................................................................................................................................................................................................................................................
Apgar score at 5 min, 7, n (%) 13 (1) 4 (3) .16
................................................................................................................................................................................................................................................................................................................................................................................
Fetal blood sampling, n (%) 151 (12) 15 (9) .43
................................................................................................................................................................................................................................................................................................................................................................................
Cesarean delivery, n (%) 73 (6) 9 (6) .88
................................................................................................................................................................................................................................................................................................................................................................................
Instrumental vaginal delivery, n (%) 128 (10) 21 (13) .27
................................................................................................................................................................................................................................................................................................................................................................................
Admission to neonatal intensive care unit, n (%) 47 (4) 2 (2) .35
................................................................................................................................................................................................................................................................................................................................................................................
Moderate or severe hypoxic ischemic
encephalopathy: Sarnat grade 2 or 3, n (%)
1 (0.1) 0 .22
................................................................................................................................................................................................................................................................................................................................................................................
Seizures, n (%) 2 (0.1) 0 .53
................................................................................................................................................................................................................................................................................................................................................................................
Intubation, n (%) 6 (0.5)c 6 (4)c  .001c
................................................................................................................................................................................................................................................................................................................................................................................
Perinatal death, n (%) 0 0 NA
................................................................................................................................................................................................................................................................................................................................................................................
Allocation to index group, n (%) 646 (49) 87 (53) .42
................................................................................................................................................................................................................................................................................................................................................................................
BDblood, base deficit calculated in blood; BDecf, base deficit calculated in the extra cellular fluid compartment; NA, not available.
a Calculated with the 2 test or the Student t tests for dichotomous or continuous variables, respectively; b Data are presented as mean SD; c Missing data were not completely at random but were
related to other subject characteristics, which indicates not to perform a complete case analysis but rather apply multiple imputation first.Schuit. Individual participant data metaanalysis of fetal ST analysis. Am J Obstet Gynecol 2013.
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observed (n  633)
Patients with at
least 1 missing value
(n  166) P valuea
Patient age at delivery, yb 29.7  5.6c 31.0  5.8c .006c
................................................................................................................................................................................................................................................................................................................................................................................
Gestational age at delivery, wkb 40.0  2.1 39.9  1.4 .30
................................................................................................................................................................................................................................................................................................................................................................................
Nulliparous, n (%) 183 (29) 41 (25) .33
................................................................................................................................................................................................................................................................................................................................................................................
Previous cesarean delivery, n (%) 41 (6) 8 (5) .59
................................................................................................................................................................................................................................................................................................................................................................................
Prolonged pregnancy: at least 42 wk, n (%) 2 (0.1) 1 (1) .86
................................................................................................................................................................................................................................................................................................................................................................................
Maternal diabetes mellitus, n (%) 32 (5) 9 (5) .98
................................................................................................................................................................................................................................................................................................................................................................................
Meconium-stained amniotic fluid, n (%) 92 (15) 29 (19) .23
................................................................................................................................................................................................................................................................................................................................................................................
Epidural anesthesia, n (%) 581 (92) 144 (87) .07
................................................................................................................................................................................................................................................................................................................................................................................
Induction of labor, n (%) 230 (36) 27 (38) .88
................................................................................................................................................................................................................................................................................................................................................................................
Birthweight, gb 3262  464c 3171  615c .038c
................................................................................................................................................................................................................................................................................................................................................................................
Birthweight 2500 g, n (%) 28 (4)c 19 (11)c .001c
................................................................................................................................................................................................................................................................................................................................................................................
Neonatal female sex, , n (%) NA NA NA
................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery pH 7.05 & BDecf  12 mmol/L, n (%) 11 (2) 2 (2) .85................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery pH 7.05 & BDblood 12 mmol/L, n (%) 14 (2) 2 (1) .83................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery pH 7.15, n (%) 113 (18) 32 (24) .12
................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery pH 7.05, n (%) 16 (3) 5 (4) .62
................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery pH 7.00, n (%) 5 (1) 2 (2) .78
................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery BDecf 12, n (%) 94 (15) 19 (17) .72................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery BDblood 12, n (%) 112 (18) 18 (16) .66................................................................................................................................................................................................................................................................................................................................................................................
Apgar score at 5 min, 7, n (%) 8 (1) 4 (3) .40
................................................................................................................................................................................................................................................................................................................................................................................
Fetal blood sampling, n (%) 279 (44) 77 (46) .66
................................................................................................................................................................................................................................................................................................................................................................................
Cesarean delivery, n (%) 157 (25) 52 (32) .07
................................................................................................................................................................................................................................................................................................................................................................................
Instrumental vaginal delivery, n (%) 180 (28) 46 (28) .03
................................................................................................................................................................................................................................................................................................................................................................................
Admission to neonatal intensive care unit, n (%) 26 (4)c 22 (14)c  .001c
................................................................................................................................................................................................................................................................................................................................................................................
Moderate or severe hypoxic ischemic
encephalopathy: Sarnat grade 2 or 3, n (%)
NA NA NA
................................................................................................................................................................................................................................................................................................................................................................................
Seizures, n (%) NA NA NA
................................................................................................................................................................................................................................................................................................................................................................................
Intubation, n (%) 3 (0.1)c 5 (3)c .01c
................................................................................................................................................................................................................................................................................................................................................................................
Perinatal death, n (%) 0 0 NA
................................................................................................................................................................................................................................................................................................................................................................................
Allocation to index group, n (%) 316 (50) 83 (50) .95
................................................................................................................................................................................................................................................................................................................................................................................
BDblood, base deficit calculated in blood; BDecf, base deficit calculated in the extra cellular fluid compartment; NA, not available.
a Calculated by the 2 test or the Student t tests for dichotomous or continuous variables, respectively; b Data are presented as mean SD; c Missing data were not completely at random but were
related to other subject characteristics, which indicates not to perform a complete case analysis but rather apply multiple imputation first.Schuit. Individual participant data metaanalysis of fetal ST analysis. Am J Obstet Gynecol 2013.
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observed (n  4110)
Patients with at
least 1 missing value
(n  939) P valuea
Patient age at delivery, yb NA NA NA
................................................................................................................................................................................................................................................................................................................................................................................
Gestational age at delivery, wkb 39.7  1.5c 39.4  2.0c  .001c
................................................................................................................................................................................................................................................................................................................................................................................
Nulliparous, n (%) 1597 (39) 324 (37) .36
................................................................................................................................................................................................................................................................................................................................................................................
Previous cesarean delivery, n (%) NA NA NA
................................................................................................................................................................................................................................................................................................................................................................................
Prolonged pregnancy: at least 42 wk, n (%) 35 (1) 7 (1) .93
................................................................................................................................................................................................................................................................................................................................................................................
Maternal diabetes mellitus, n (%) 88 (2) 16 (2) .71
................................................................................................................................................................................................................................................................................................................................................................................
Meconium-stained amniotic fluid, n (%) 936 (23) 207 (23) .73
................................................................................................................................................................................................................................................................................................................................................................................
Epidural anesthesia, n (%) 1627 (40)c 330 (35)c .01c
................................................................................................................................................................................................................................................................................................................................................................................
Induction of labor, n (%) 709 (17) 157 (17) .96
................................................................................................................................................................................................................................................................................................................................................................................
Birthweight, gb 3585  517c 3485  582c  .001c
................................................................................................................................................................................................................................................................................................................................................................................
Birthweight 2500 g, n (%) 74 (2)c 44 (5)c  .001c
................................................................................................................................................................................................................................................................................................................................................................................
Neonatal female sex, , n (%) 1930 (47) 446 (49) .32
................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery pH 7.05 & BDecf 12 mmol/L, n (%) 43 (1) 3 (1) .84................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery pH 7.05 & BDblood 12 mmol/L, n (%) NA NA NA................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery pH 7.15, n (%) 788 (19)c 72 (33)c  .001c
................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery pH 7.05, n (%) 137 (3) 13 (6) .06
................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery pH 7.00, n (%) 42 (1)c 9 (4)c  .001c
................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery BDecf 12, n (%) 62 (2) 3 (5) .14................................................................................................................................................................................................................................................................................................................................................................................
Cord-artery BDblood 12, n (%) NA NA NA................................................................................................................................................................................................................................................................................................................................................................................
Apgar score at 5 min, 7, n (%) 44 (1) 17 (2) .07
................................................................................................................................................................................................................................................................................................................................................................................
Fetal blood sampling, n (%) NA NA NA
................................................................................................................................................................................................................................................................................................................................................................................
Cesarean delivery, n (%) 367 (9) 80 (9) .74
................................................................................................................................................................................................................................................................................................................................................................................
Instrumental vaginal delivery, n (%) 410 (10)c 132 (14)c  .001c
................................................................................................................................................................................................................................................................................................................................................................................
Admission to neonatal intensive care unit, n (%) 282 (7)c 105 (11)c  .001c
................................................................................................................................................................................................................................................................................................................................................................................
Moderate or severe hypoxic ischemic
encephalopathy: Sarnat grade 2 or 3, n (%)
NA NA NA
................................................................................................................................................................................................................................................................................................................................................................................
Seizures, n (%) NA NA NA
................................................................................................................................................................................................................................................................................................................................................................................
Intubation, n (%) NA NA NA
................................................................................................................................................................................................................................................................................................................................................................................
Perinatal death, n (%) NA NA NA
................................................................................................................................................................................................................................................................................................................................................................................
Allocation to index group, n (%) 2085 (51) 480 (51) .86
................................................................................................................................................................................................................................................................................................................................................................................
BDblood, base deficit calculated in blood; BDecf, base deficit calculated in the extra cellular fluid compartment; NA, not available.
a Calculated by the 2 test or the Student t tests for dichotomous or continuous variables, respectively; b Data are presented as mean SD; c Missing data were not completely at random but were
related to other subject characteristics, which indicates not to perform a complete case analysis but rather apply multiple imputation first.Schuit. Individual participant data metaanalysis of fetal ST analysis. Am J Obstet Gynecol 2013.
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